Product
90Y-DOTA-3-Tyr-Octreotide
1 clinical trial
4 indications
Indication
Neuroendocrine TumorIndication
malignantIndication
Neuroendocrine Tumor (Gastrointestinal)Indication
Hormone SecretingClinical trial
Phase 1 Trial Using 131I MIBG and 90Y DOTATOC in a Dosimetrically Determined Optimal Combination for Therapy of Selected Patients With Midgut Neuroendocrine Tumors.Status: Active (not recruiting), Estimated PCD: 2025-12-01